🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2-positive, Metastatic Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease NCT07542496n/a2 sites📍 Algiers📍 Algiers Société Algérienne de Formation et Recherche en Oncologie DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients NCT06388122n/a1 site📍 Jacksonville Mayo Clinic · Tests: Biospecimen Collection A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer NCT07455188n/a1 site📍 Zhejiang Zhejiang Cancer Hospital · Tests: Antitumor treatment plan SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases NCT04923542Phase 1, Phase 22 sites📍 Tampa📍 Columbus H. Lee Moffitt Cancer Center and Research Institute · Tests: Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites📍 La Jolla📍 Los Angeles📍 Port Saint Lucie Regor Pharmaceuticals Inc. · Tests: RGT-419B, RGT-419B in combination with hormonal therapy SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance NCT07503717NA1 site📍 Beaumont Royal College of Surgeons, Ireland · Tests: Brain Magnetic Resonance Imaging (MRI) with Contrast ARX788 in HER2-positive Metastatic Breast Cancer Patients NCT06663748Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: ARX788 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer NCT07112053Phase 21 site📍 Seattle University of Washington · Tests: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4… Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer NCT05744687Phase 2, Phase 39 sites📍 Fuzhou📍 Guangzhou📍 Guiyang Shanghai Pharmaceuticals Holding Co., Ltd · Tests: SPH4336 Tablets 400mg, SPH4336 Tablets Placebo RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study NCT07030569n/a1 site📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Trastuzumab deruxtecan (DS-8201a) Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure NCT07708194Phase 1, Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: entinostat, Pyrotinib, endocrine therapy A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Abemaciclib, Radiation Therapy A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites📍 Bengbu📍 Hefei📍 Hefei Genor Biopharma Co., Ltd. · Tests: GB491 combined with Letrozole, Placebo combined with Letrozole Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584Phase 21 site📍 Orange University of California, Irvine · Tests: Fulvestrant, Anastrozole, Abemaciclib PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer NCT04517838n/a1 site📍 Jacksonville Mayo Clinic · Tests: Biospecimen Collection A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer NCT07701941Phase 1, Phase 272 sites📍 Los Angeles📍 Stanford📍 Aurora Daiichi Sankyo · Tests: Patritumab deruxtecan, Trastuzumab deruxtecan RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939Phase 2, Phase 3206 sites📍 Huntsville📍 Gilbert📍 San Francisco Hoffmann-La Roche · Tests: RO7771950, Tucatinib, Trastuzumab, Capecitabine Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer NCT06207734Phase 213 sites📍 Berlin📍 Bremen📍 Dortmund Institut für Klinische Krebsforschung IKF GmbH at Krankenha… · Tests: Continuation of CDK4/6 inhibitor Palbociclib, Discontinuation of CDK4/6 inhibitor Palbociclib, Continuation of CDK4/6 i… Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. NCT06450314Phase 21 site📍 Rennes UNICANCER · Tests: Discontinuation of the anti-HER2 maintenance therapy, Monitoring with signatera test Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site📍 La Jolla University of California, San Diego · Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physicia… Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer NCT05955170Phase 213 sites📍 Clermont-Ferrand📍 Amiens📍 Avignon Institut Curie · Tests: Tucatinib in Combination of Oral VP16 and trastuzumab ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673Phase 21 site📍 San Francisco Laura Huppert, MD, BA · Tests: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management NCT05362760Phase 454 sites📍 Aalen📍 Amberg📍 Aschaffenburg Prof. Wolfgang Janni · Tests: Abemaciclib + Aromatase Inhibitor, Abemaciclib + Fulvestrant
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy